{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:37:07Z","timestamp":1789123027317,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangxi Provincial Health Commission science and technology plan","award":["202130039"],"award-info":[{"award-number":["202130039"]}]},{"name":"Jiangxi Provincial Health Commission science and technology plan","award":["SKJP1320242026"],"award-info":[{"award-number":["SKJP1320242026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83174-0","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T20:20:12Z","timestamp":1735590012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TMEM101 expression and its impact on immune cell infiltration and prognosis in hepatocellular carcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Lingyun","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"83174_CR1","doi-asserted-by":"publisher","first-page":"116109","DOI":"10.1016\/j.biopha.2023.116109","volume":"171","author":"W Wang","year":"2024","unstructured":"Wang, W., Zhou, Y., Li, W., Quan, C. & Li, Y. Claudins and hepatocellular carcinoma. Biomed. Pharmacother. 171, 116109 (2024).","journal-title":"Biomed. Pharmacother"},{"key":"83174_CR2","doi-asserted-by":"crossref","unstructured":"Luo, X. et al. Hepatocellular carcinoma: Signaling pathways, targeted therapy, and immunotherapy. MedComm 2024(5), e474 (2020).","DOI":"10.1002\/mco2.474"},{"key":"83174_CR3","doi-asserted-by":"publisher","first-page":"e430028","DOI":"10.1200\/EDBK_430028","volume":"44","author":"P Ntellas","year":"2024","unstructured":"Ntellas, P. & Chau, I. Updates on systemic therapy for hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book. 44, e430028 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"83174_CR4","doi-asserted-by":"crossref","unstructured":"Christou, C., Stylianou, A. & Gkretsi, V. Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker. Cells 13 (2024).","DOI":"10.3390\/cells13020136"},{"key":"83174_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"83174_CR6","doi-asserted-by":"publisher","first-page":"188720","DOI":"10.1016\/j.bbcan.2022.188720","volume":"1877","author":"XY Li","year":"2022","unstructured":"Li, X. Y., Shen, Y., Zhang, L., Guo, X. & Wu, J. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim. Biophys. Acta Rev. Cancer 1877, 188720 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"83174_CR7","doi-asserted-by":"publisher","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","volume":"555","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Wang, Y., Gao, P. & Ding, J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett. 555, 216038 (2023).","journal-title":"Cancer Lett."},{"key":"83174_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N Engl. J. Med."},{"key":"83174_CR9","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.18632\/aging.202487","volume":"13","author":"J Duan","year":"2021","unstructured":"Duan, J. et al. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging (Albany NY) 13, 5585\u20135606 (2021).","journal-title":"Aging (Albany NY)"},{"key":"83174_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3389\/fphar.2018.01345","volume":"9","author":"K Schmit","year":"2018","unstructured":"Schmit, K. & Michiels, C. TMEM proteins in cancer: A review. Front. Pharmacol. 9, 1345 (2018).","journal-title":"Front. Pharmacol."},{"key":"83174_CR11","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1038\/sj.onc.1206406","volume":"22","author":"A Matsuda","year":"2003","unstructured":"Matsuda, A. et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 22, 3307\u20133318 (2003).","journal-title":"Oncogene"},{"key":"83174_CR12","doi-asserted-by":"crossref","unstructured":"Gao, Q. et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179 561\u2009\u20137. (2019).","DOI":"10.1016\/j.cell.2019.08.052"},{"key":"83174_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.7150\/jca.31435","volume":"11","author":"W Chen","year":"2020","unstructured":"Chen, W. et al. Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis. J. Cancer. 11, 403\u2013413 (2020).","journal-title":"J. Cancer"},{"key":"83174_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jhep.2022.03.008","volume":"77","author":"P Lin","year":"2022","unstructured":"Lin, P. & Yang, H. EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma. J. Hepatol. 77, 879\u2013880 (2022).","journal-title":"J. Hepatol."},{"key":"83174_CR15","doi-asserted-by":"publisher","first-page":"113076","DOI":"10.1016\/j.yexcr.2022.113076","volume":"414","author":"G Chi","year":"2022","unstructured":"Chi, G. et al. SMYD5 acts as a potential biomarker for hepatocellular carcinoma. Exp. Cell. Res. 414, 113076 (2022).","journal-title":"Exp. Cell. Res."},{"key":"83174_CR16","doi-asserted-by":"publisher","first-page":"575776","DOI":"10.3389\/fgene.2020.575776","volume":"11","author":"J Rao","year":"2020","unstructured":"Rao, J., Wu, X., Zhou, X., Deng, R. & Ma, Y. TMEM205 is an independent prognostic factor and is associated with immune cell infiltrates in hepatocellular carcinoma. Front. Genet. 11, 575776 (2020).","journal-title":"Front. Genet."},{"key":"83174_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/tgh-23-108","volume":"9","author":"N Zhang","year":"2024","unstructured":"Zhang, N. et al. TMEM43 promotes the development of hepatocellular carcinoma by activating VDAC1 through USP7 deubiquitination. Transl Gastroenterol. Hepatol. 9, 9 (2024).","journal-title":"Transl Gastroenterol. Hepatol."},{"key":"83174_CR18","doi-asserted-by":"crossref","unstructured":"Chen, D. et al. Characterization of the clinical significance and immunological landscapes of a novel TMEMs signature in hepatocellular carcinoma and the contribution of TMEM201 to hepatocarcinogenesis. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms241210285"},{"key":"83174_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41575-022-00620-y","volume":"19","author":"P Johnson","year":"2022","unstructured":"Johnson, P., Zhou, Q., Dao, D. Y. & Lo, Y. M. D. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 19, 670\u2013681 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"83174_CR20","doi-asserted-by":"crossref","unstructured":"Tayob, N., Kanwal, F., Alsarraj, A., Hernaez, R. & El-Serag, H. B. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): A Phase 3 biomarker study in the United States. Clin. Gastroenterol. Hepatol. ; 21: (2023). 415\u2009\u2013\u200923.e4.","DOI":"10.1016\/j.cgh.2022.01.047"},{"key":"83174_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imm.13751","volume":"172","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma. Immunology 172, 21\u201345 (2024).","journal-title":"Immunology"},{"key":"83174_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/2326-6066.CIR-16-0216","volume":"5","author":"L Vujanovic","year":"2017","unstructured":"Vujanovic, L. et al. Tumor-derived \u03b1-fetoprotein directly drives human natural killer-cell activation and subsequent cell death. Cancer Immunol. Res. 5, 493\u2013502 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"83174_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jhep.2022.02.018","volume":"77","author":"A Husain","year":"2022","unstructured":"Husain, A. et al. Ephrin-A3\/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. J. Hepatol. 77, 383\u2013396 (2022).","journal-title":"J. Hepatol."},{"key":"83174_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13072-017-0115-7","volume":"10","author":"BL Kidder","year":"2017","unstructured":"Kidder, B. L., Hu, G., Cui, K. & Zhao, K. SMYD5 regulates H4K20me3-marked heterochromatin to safeguard ES cell self-renewal and prevent spurious differentiation. Epigenetics Chromatin 10, 8 (2017).","journal-title":"Epigenetics Chromatin"},{"key":"83174_CR25","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1158\/1078-0432.CCR-12-3363","volume":"19","author":"WW Zhu","year":"2013","unstructured":"Zhu, W. W. et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin. Cancer Res. 19, 3944\u20133954 (2013).","journal-title":"Clin. Cancer Res."},{"key":"83174_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.aohep.2019.09.002","volume":"19","author":"MM Omran","year":"2020","unstructured":"Omran, M. M. et al. A combination of \u03b1-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann. Hepatol. 19, 179\u2013185 (2020).","journal-title":"Ann. Hepatol."},{"key":"83174_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/iub.2458","volume":"73","author":"A Gowhari Shabgah","year":"2021","unstructured":"Gowhari Shabgah, A. et al. Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy. IUBMB Life 73, 659\u2013669 (2021).","journal-title":"IUBMB Life"},{"key":"83174_CR28","doi-asserted-by":"crossref","unstructured":"Sas, Z., Cendrowicz, E., Weinh\u00e4user, I. & Rygiel, T. P. Tumor microenvironment of hepatocellular carcinoma: Challenges and opportunities for new treatment options. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23073778"},{"key":"83174_CR29","doi-asserted-by":"crossref","unstructured":"Chen, D., Li, X., Li, H., Wang, K. & Tian, X. Identification of immune-related prognostic mRNA and lncRNA in patients with hepatocellular carcinoma. J Oncol. 2022 5313149 (2022).","DOI":"10.1155\/2022\/5313149"},{"key":"83174_CR30","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.2147\/IJGM.S326535","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Wang, Z. & Huang, Y. Comprehensive analyses of the infiltrating immune cell landscape and its clinical significance in hepatocellular carcinoma. Int. J. Gen. Med. 14, 4695\u20134704 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"83174_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1186\/s12885-022-09872-y","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Zou, J. & Chen, R. An M0 macrophage-related prognostic model for hepatocellular carcinoma. BMC Cancer 22, 791 (2022).","journal-title":"BMC Cancer"},{"key":"83174_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1158\/1535-7163.MCT-23-0660","volume":"23","author":"YT Liu","year":"2024","unstructured":"Liu, Y. T., Mao, Z. W., Ding, Y. & Wang, W. L. Macrophages as targets in hepatocellular carcinoma therapy. Mol. Cancer Ther. 23, 780\u2013790 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"83174_CR33","doi-asserted-by":"publisher","first-page":"174844","DOI":"10.1016\/j.ejphar.2022.174844","volume":"920","author":"Y Pang","year":"2022","unstructured":"Pang, Y. et al. Inhibition of abnormally activated HIF-1\u03b1-GLUT1\/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives. Eur. J. Pharmacol. 920, 174844 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"83174_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D","volume":"194","author":"A Nocito","year":"2001","unstructured":"Nocito, A. et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J. Pathol. 194, 349\u2013357 (2001).","journal-title":"J. Pathol."},{"key":"83174_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"83174_CR36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"83174_CR37","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013d92 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83174-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T14:08:14Z","timestamp":1735654094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83174-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["83174"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83174-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study adhered to the Declaration of Helsinki and received approval from the Ethics Committee of Jiangxi Provincial People\u2019s Hospital (Approval No: 20240609). All participants signed the informed consents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"31847"}}